ADVFN Logo ADVFN
Donnée du Marché
Actualité
Outils
Donnée du Marché
Discover

Hot Features

Follow Feed

Rester connecter avec les traders et investisseurs dans notre communauté Follow Feed.

Flux des Options

Explorez des données complètes sur les options et utilisez les filtres avancés avec Options Flow.

Moniteur

Organisez et surveillez vos d'actions et actifs avec le Moniteur.
Se connecter Premium IconPremium Help Menu
CAC 40
7 570,48
-0,82%
Dow Jones
40 211,72
0,53%
DAX
18 468,53
-0,71%
Brent Oil
83,585
-0,90%
Bitcoin
62 847,02
-3,09%
Registration Strip Icon for monitor Surveillez plusieurs cotations en temps réel des principales bourses, telles que Euronext Paris, NASDAQ, NYSE, AMEX, Bovespa et plus encore.
S'inscrire
  1. Accueil
  2. Investir
  3. Actions
  4. Etats-Unis
  5. NASDAQ
  6. Intellia Therapeutics Inc (NTLA)

  7. Intellia Therapeutics Inc (NTLA) Actualités

NTLA

Intellia Therapeutics (NTLA)

Intellia Therapeutics Inc
De:
Trier par:
 Showing the most relevant articles for your search:NASDAQ:NTLA
DateHeureSourceTitreSymboleSociété
26/02/202413h04Edgar (US Regulatory)Form 424B5 - Prospectus [Rule 424(b)(5)]NASDAQ:NTLAIntellia Therapeutics Inc
23/02/202423h17Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:NTLAIntellia Therapeutics Inc
22/02/202422h11Edgar (US Regulatory)Form S-8 - Securities to be offered to employees in employee benefit plansNASDAQ:NTLAIntellia Therapeutics Inc
22/02/202422h02Edgar (US Regulatory)Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405]NASDAQ:NTLAIntellia Therapeutics Inc
22/02/202413h30GlobeNewswire Inc.Intellia Therapeutics Announces Fourth Quarter and Full-Year 2023 Financial Results and Highlights Recent Company ProgressNASDAQ:NTLAIntellia Therapeutics Inc
15/02/202413h30GlobeNewswire Inc.Intellia Therapeutics and ReCode Therapeutics Announce Strategic Collaboration to Develop Novel Gene Editing Therapies for Cystic FibrosisNASDAQ:NTLAIntellia Therapeutics Inc
14/02/202413h30GlobeNewswire Inc.Intellia Therapeutics to Hold Conference Call to Discuss Fourth Quarter and Full-Year 2023 Earnings and Company UpdatesNASDAQ:NTLAIntellia Therapeutics Inc
31/01/202423h00GlobeNewswire Inc.Intellia Therapeutics Announces Publication of Positive Interim Phase 1 Data for NTLA-2002 in Patients with Hereditary Angioedema in the New England Journal of MedicineNASDAQ:NTLAIntellia Therapeutics Inc
29/01/202422h00Edgar (US Regulatory)Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]NASDAQ:NTLAIntellia Therapeutics Inc
10/01/202422h15Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:NTLAIntellia Therapeutics Inc
08/01/202422h05Edgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:NTLAIntellia Therapeutics Inc
04/01/202422h01GlobeNewswire Inc.Intellia Therapeutics Highlights its Three-Year Strategic Priorities and Anticipated 2024 Key MilestonesNASDAQ:NTLAIntellia Therapeutics Inc
24/11/202315h30Edgar (US Regulatory)Form S-3ASR - Automatic shelf registration statement of securities of well-known seasoned issuersNASDAQ:NTLAIntellia Therapeutics Inc
14/11/202313h30GlobeNewswire Inc.Intellia Therapeutics Receives European Union Orphan Drug Designation for NTLA-2002, an Investigational In Vivo CRISPR Genome Editing Treatment for Hereditary AngioedemaNASDAQ:NTLAIntellia Therapeutics Inc
09/11/202322h05Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:NTLAIntellia Therapeutics Inc
09/11/202313h30GlobeNewswire Inc.Intellia Therapeutics Announces Third Quarter 2023 Financial Results and Highlights Recent Company ProgressNASDAQ:NTLAIntellia Therapeutics Inc
02/11/202312h00GlobeNewswire Inc.Intellia Presents New Interim Data from the Ongoing Phase 1 Study of NTLA-2001 at the 4th International ATTR Amyloidosis MeetingNASDAQ:NTLAIntellia Therapeutics Inc
26/10/202313h30GlobeNewswire Inc.Intellia Therapeutics to Present Updated Data from Ongoing Phase 1 Study of NTLA-2001 for the Treatment of Transthyretin (ATTR) Amyloidosis and Hold Conference Call to Discuss Third Quarter 2023 Earnings in NovemberNASDAQ:NTLAIntellia Therapeutics Inc
18/10/202313h00GlobeNewswire Inc.Intellia Therapeutics Announces FDA Clearance of Investigational New Drug (IND) Application to Initiate a Pivotal Phase 3 Trial of NTLA-2001 for the Treatment of Transthyretin (ATTR) Amyloidosis with CardiomyopathyNASDAQ:NTLAIntellia Therapeutics Inc
13/10/202314h38GlobeNewswire Inc.Intellia Therapeutics Receives Priority Medicines (PRIME) Designation From the European Medicines Agency for NTLA-2002, an Investigational In Vivo CRISPR Genome Editing Treatment for Hereditary AngioedemaNASDAQ:NTLAIntellia Therapeutics Inc
03/10/202313h00GlobeNewswire Inc.Regeneron and Intellia Announce Expanded Research Collaboration to Develop CRISPR-Based Therapies for the Treatment of Neurological and Muscular DiseasesNASDAQ:NTLAIntellia Therapeutics Inc
03/08/202313h30GlobeNewswire Inc.Intellia Therapeutics Announces Second Quarter 2023 Financial Results and Highlights Recent Company ProgressNASDAQ:NTLAIntellia Therapeutics Inc
27/07/202313h30GlobeNewswire Inc.Intellia Therapeutics to Hold Conference Call to Discuss Second Quarter 2023 Earnings and Company UpdatesNASDAQ:NTLAIntellia Therapeutics Inc
22/06/202323h53Edgar (US Regulatory)Statement of Changes in Beneficial Ownership (4)NASDAQ:NTLAIntellia Therapeutics Inc
21/06/202312h00Edgar (US Regulatory)Report of Proposed Sale of Securities (144)NASDAQ:NTLAIntellia Therapeutics Inc
16/06/202322h14Edgar (US Regulatory)Current Report Filing (8-k)NASDAQ:NTLAIntellia Therapeutics Inc
11/06/202314h30GlobeNewswire Inc.Intellia Therapeutics Announces New Positive Clinical Data from Phase 1 Study of NTLA-2002, an Investigational In Vivo CRISPR Genome Editing Treatment for Hereditary Angioedema (HAE)NASDAQ:NTLAIntellia Therapeutics Inc
05/06/202322h01GlobeNewswire Inc.Intellia Therapeutics Announces Retirement of Jean-François Formela, M.D. From its Board of DirectorsNASDAQ:NTLAIntellia Therapeutics Inc
04/05/202322h15Edgar (US Regulatory)Quarterly Report (10-q)NASDAQ:NTLAIntellia Therapeutics Inc
04/05/202313h30GlobeNewswire Inc.Intellia Therapeutics Announces First Quarter 2023 Financial Results and Highlights Recent Company ProgressNASDAQ:NTLAIntellia Therapeutics Inc
 Showing the most relevant articles for your search:NASDAQ:NTLA

Dernières Valeurs Consultées

LSE
30GK
Bristol W.4q%
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

France
Société
Entreprise
Popular
Obtenir l'application
App Store
Google Play

Assistance: support@advfn.fr

En accédant aux services disponibles de ADVFN, vous acceptez les Conditions Générales de ADVFN Conditions Générales

© 2024 ADVFN PLC - Tous droits réservés